MYC and B-cell non-Hodgkin lymphoma: Interestingly, the Bruton’s tyrosine kinase inhibitor ibrutinib, indicated for B-cell lymphoma and leukemia, is a promising therapeutic against MYC proto-oncogene, bHLH transcription factor (MYC)-amplified EAC tumors, thus further supporting the narrative of innate immune involvement in EAC development.172